



ASX Announcement

For immediate release

October 1, 2007

U.S. Food & Drug Administration approves Afluria[®] influenza virus vaccine, for marketing in the U.S.

CSL Limited one of the world's leading manufacturers of influenza vaccine, announced today that the U.S. Food and Drug Administration (FDA) has approved its influenza virus vaccine, to be known as Afluria[®] in the U.S., for active immunisation to prevent influenza disease caused by influenza virus types A and B present in the vaccine in adults 18 years and older. Today's approval marks the company's first entry into the U.S. vaccine market.

Afluria[®] will be made available in both single-dose, thiomersal-free, pre-filled syringes and in multidose vials to provide choice and convenience to caregivers who administer it. CSL plans to begin delivering shipments to the U.S. during the 2007-2008 flu season.

For more information about CSL Limited, visit www.csl.com.au

Media Contact:

Dr Rachel David
Director of Public Affairs
Phone: +61 401 775 779

Investor Contact:

Mark Dehring
Director of Investor Relations
Phone: +61 3 9389 2818
Email: mark.dehring@csl.com.au